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We describe the burden of influenza  B infections in Italy over a 
12-year study period. Influenza  A and B  viruses co-circulated 
throughout the period, with numbers of influenza B cases approach-
ing or exceeding those of influenza A during three influenza seasons. 
Influenza B virus infections led to fewer admissions to an intensive 
care unit (ICU) and a lower mortality rate than influenza A from 
2010 to 2015. However, only 16% of those admitted to ICU with 
influenza B had been immunized. This highlights the need for con-
sistent influenza vaccination for identified risk groups. Our study 
demonstrates that influenza B virus infections are associated with 
substantial morbidity and that influenza surveillance and interven-
tions including vaccination and treatment are still suboptimal. Our 
findings have important public health implications. Incorporating 
virus and epidemiological data will help obtain more accurate esti-
mates of influenza disease burden and result in a better selection of 
influenza prevention and control strategies.
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Summary
Introduction 
The societal burden of seasonal influenza epidemics is 
quite heavy, with approximately 3-5 million cases and 
250,000-500,000 estimated deaths worldwide every 
year  [1] and a large economic impact, which includes 
both direct and indirect costs  [2,  3]. Conventionally, 
attention has been directed toward influenza A, which 
accounts for the majority of influenza cases in most sea-
sons [4-7]. However, influenza B can account for a con-
siderable proportion of total cases [8]. Since the 1980s, 
influenza B viruses have belonged to two antigenically 
distinct lineages, called the Victoria and Yamagata line-
ages  [9]; this has constituted a challenge for seasonal 
influenza vaccines, as only one influenza  B strain is 
included in the trivalent vaccine. Studies in the United 
States have shown that the frequent influenza B vaccine 
mismatches of recent years have been associated both 
with substantial increases in cases, hospitalizations and 
deaths (up to 970,000 cases, with 8200 hospitalizations 
and 485 deaths annually, in the USA) [10], and with high 
influenza-related medical costs and costs due to produc-
tivity loss [11]. 
Despite the important role of influenza B, much of the 
published scientific literature regarding the epidemiol-
ogy of influenza has focused on influenza A, and we still 
have a relatively poor understanding of the global epi-
demiology and disease burden of influenza B. Several 
studies have reported on the burden of disease attribut-
able to influenza  B in a single season, or during con-
secutive seasons in a single country [12, 13]. In order to 
improve our understanding of the burden and epidemiol-
ogy of influenza B, we reviewed the influenza B viruses 
circulating in Italy from 2000 to 2015.
Materials and methods 
The National Influenza Sentinel 
Surveillance System 
In Italy, the Influenza Sentinel Surveillance System (IN-
FLUNET) was implemented nationwide in the 1999-2000 
season by the Influnet working group [12]. INFLUNET is 
based on the voluntary participation of an average of 830 
(range 648-902) general practitioners (including paediatri-
cians) per year, covering about 1.5-2% of the national pop-
ulation in all Italian regions. The system aims to monitor 
the incidence of influenza-like illness (ILI) and to deter-
mine the extent, timing and severity of seasonal epidemics.
GPs are asked to report ILI cases (defined as acute onset 
of fever +  respiratory symptoms +  one of the follow-
ing symptoms: headache, general discomfort, asthenia) 
weekly (from week 42 to week 17) using standardized 
forms. Specific information regarding age (0-14, 15-64, 
>  64  years) and influenza vaccine status are also col-
lected. We excluded the first years of data collection and 
focused the analysis on Influnet data collected from the 
2005/2006 to 2014/2015 seasons.
The National Virological Surveillance 
System
Influenza virological surveillance in Italy is routinely 
carried out, between week 46 and week 17 of the fol-
lowing year, by the National WHO (World Health Or-
ganization) Influenza Centre at the Istituto Superiore 
di Sanità (NIC-ISS), in collaboration with a network of 
15 peripheral laboratories located in 14 of the 21  Ital-
ian regions. The main objective of these activities is to 
rapidly characterize the influenza viruses circulating in 
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the country and to identify antigenic variants emerging 
in human populations during the winter season, in or-
der to update the vaccine composition, in collaboration 
with the WHO and ECDC (European Centre for Disease 
Prevention and Control). During the virological surveil-
lance period, sampling kits are sent out to a random 
sample of GPs participating in the INFLUNET surveil-
lance system, who collect throat swabs from the first ILI 
patients seen each week. Collected swabs are then sent 
to the regional Reference Laboratories for influenza di-
agnosis, and the isolated strains are characterized at the 
Regional Laboratory or directly sent to the NIC-ISS for 
further molecular and antigenic analyses. Overall results 
obtained throughout the country are reported to the NIC-
ISS weekly by means of web-based electronic forms. 
Every year, approximately 2000 samples are collected, 
with a proportion of positive specimens of about 34%. 
Our analysis included virological surveillance data col-
lected from the 2000/2001 to 2011/2012 seasons.
Surveillance of laboratory-confirmed 
severe cases
A web-based data collection form for the surveillance of 
severe confirmed hospitalised cases and deaths due to pan-
demic influenza was drawn up in mid-September 2009. 
Since then, regional and local authorities have filled in 
forms during the influenza season (October-April); the 
data are analysed weekly at the national level (by the ISS 
and the Ministry of Health). Our analysis included viro-
logical surveillance data collected from the 2010/2011 
to 2014/2015 seasons, as all confirmed cases during the 
2009/2010 season were due to A/H1N1pdm09 virus. 
Results
From the 2005/2006 to 2014/2015 seasons, an estimat-
ed average number of approximately 4,800.000  ILI 
cases were reported to the surveillance system 
(Tab. I). Most were in the 0-5-year age-class. The na-
tional database that was used for the analysis included 
40,000 ILI cases, with testing of samples from cases 
that occurred between 2000/2001 and 2011/2012. 
During the study period, several waves of infections 
by influenza A and B viruses were observed in Italy 
Fig. 1. Number of influenza A and B virus infections, Italy, 2000/2001 – 2011/2012.
* During 2009/2010 only A/H1N1pdm09 virus circulated
Tab. I. Distribution of estimated influenza-like illness cases and cu-
mulative incidence by season, Italy, 2005/2006 – 2014/2015.
Season Peak week Cumulative incidence
Estimated ILI 
cases
2005/2006 12 3.9 2,400.000
2006/2007 5 5.7 3,700.000
2007/2008 7 6.9 4,700.000
2008/2009 4 7,2 4,100.000
2009/2010 46 9.7 5,600.000
2010/2011 5 10.3 5,400.000
2011/2012 5 8.6 5,000.000
2012/2013 6 10.5 6,200.000
2013/2014 6 7.8 4,500.000
2014/2015 4 10.8 6,300.000
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(Fig. 1). In detail, 11,488 influenza cases were con-
firmed in the study period: 9,842 influenza  A cases 
and 1,646 influenza B cases. Influenza A and B virus-
es co-circulated during most influenza seasons, with 
numbers of influenza B infections approaching or ex-
ceeding those of influenza A virus during three sea-
sons in the study period considered (2001/02, 2007/08 
and 2012/13). The number of samples tested for in-
fluenza viruses by PCR in Italy increased by a fac-
tor of 1.5 over this period, from an average of 2,774 
per season in the period 2000-2007 to an average of 
4,312 per season in 2008-2012. Influenza B appeared 
to be relatively more frequent among older children; 
A(H1N1)pdm2009 among young and older adults, 
and A(H3N2) among the elderly. On average, the pro-
portion of influenza B cases on the total of tested sam-
ples was 23% (range < 1-78%) (Fig. 2).
Severity of influenza B
From 2010/2011 to 2014/15, on a total of 1,545 se-
vere confirmed influenza cases reported to the sur-
veillance system (Tab.  I), 102 were confirmed influ-
enza B virus-infected individuals admitted to ICU; 2 
were pregnant (both in the third trimester); 7 needed 
extracorporeal membrane oxygenation (ECMO) treat-
ment, and 24  died. The median age was 63  years 
(range 0-92), 58 were male, and 16 were vaccinated 
almost 15 days before symptom onset. The median 
age of the individuals who died was 76 (range 39-85). 
Of the 102 severe influenza B patients, 73 belonged 
to groups recommended for vaccination (65  years 
and older or a clinical risk group), but only 16 had 
actually received the seasonal influenza vaccination. 
Most of the influenza  B cases were reported during 
the 2012/2013 season, when the B virus co-circulated 
with the A/H1N1pdm09. 
Discussion
Our results on influenza B virus infections in Italy are 
timely, in view of the recent introduction of a tetrava-
lent influenza vaccine containing influenza B viruses 
of both the Victoria and Yamagata lineages. Our study 
reveals that influenza  B virus was the predominant 
overall cause of influenza in two of the 13 influenza 
seasons from 2000/01 through 2012/13. However, 
circulation of the B  virus during the inter-pandemic 
season was always demonstrated. Similar patterns of 
influenza B virus circulation have been described in 
the US, Europe and Hong Kong [12-13]. In Italy, the 
proportion of influenza  B cases in the study period 
averaged 23% (range < 1-78%), a value similar to the 
European (23% (1-60%)) and US (24% (<  1-44%)) 
averages [14].
In our study, < 1% of all ILI cases are tested for influ-
enza each season, and very few B  viruses were anti-
genically and genetically characterized, thus reducing 
the opportunity to identify the co-circulation of the two 
lineages in Italy. However, evidence from two Northern 
Italian regions clearly demonstrated a complete or par-
tial mismatch in the 2001/2002, 2004/2005, 2005/2006, 
2007/2008, 2008/2009, 2010/2011, and 2011/2012 sea-
sons; this was almost always due to co-circulation of the 
two lineages [15-17]. 
Influenza is generally recognised as an important dis-
ease which causes high excess mortality among the el-
derly, although children have been shown to play an 
important role in its transmission  [18-19]. Unlike the 
influenza  A(H3N2) virus, the B  virus predominantly 
infects children and young adults and is generally rec-
ognised as a mild influenza virus [20]. Data on severe 
influenza B virus infections and mortality are limited. 
A large study conducted in the US reported that 25% 
of all influenza-related mortality could be attributed to 
influenza B virus [21]. This is higher than the percent-
age seen in the present study, in which influenza B in-
Fig. 2. Influenza B circulation as a proportion of the total percentage of all circulating influenza strains, Italy 2001/2002 – 2010/2011 seasons.
Tab. II. Distribution of confirmed severe cases, by influenza virus, 
Italy, 2010/2011 – 2014/2015.
Season A/H1N1v A/H3N2 A/non sub-typed B Total
2010/2011 517 0 11 10 538
2011/2012 7 33 1 1 42
2012/2013 143 8 7 61 219
2013/2014 61 23 7 1 92
2014/2015 494 87 44 29 654
Total 1,222 151 70 102 1,545
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fections accounted for 6% of all influenza virus-related 
deaths (24/428) during the period considered, but is 
similar to figures reported for Scotland  [22]. Among 
those admitted to ICU with influenza  B infections, 
7% needed ECMO treatment, 2% were pregnant, and 
23.5% died. 
Influenza immunisation is recommended in Italy for 
specific groups with an increased risk of complica-
tions following influenza infection (e.g. > 65 years old, 
> 6 months with chronic conditions, healthcare person-
nel, pregnant women in their second or third trimes-
ter etc.)  [23]. Only 16% of those treated in ICU who 
should have been vaccinated had received the seasonal 
influenza vaccine, and  70% of those treated in ICU 
were included in the target categories of national rec-
ommendations. 
The magnitude of the problem created by mismatching 
between circulating influenza B strains and the influen-
za B lineage contained in the vaccine varies by season. 
The most striking recent examples occurred during the 
2005-2006 and 2007-2008 seasons. In 2005-2006, the 
influenza B component of the northern hemisphere in-
fluenza vaccine was of the B/Yamagata lineage, but 81-
91% of the circulating influenza B viruses antigenically 
characterized in the US and Europe were of the B/Victo-
ria lineage, and influenza B was found in 34-60% of all 
samples [14]. Similarly, in 2007-2008, the influenza B 
component of the vaccine was of the B/Victoria line-
age, but 98-99% of the circulating influenza B viruses 
characterized in the US and Europe belonged to the B/
Yamagata lineage [14]. 
Unfortunately, as very few B influenza viruses in Italy 
were genotyped, information on the antigenic character-
istics of circulating  B viruses was not available at the 
national level.
Our study demonstrates that influenza  B virus infec-
tions are associated with substantial morbidity and that 
influenza surveillance and interventions including vac-
cination and treatment are still suboptimal. Our findings 
have important public health implications. Incorporating 
viral and epidemiological data will help obtain more ac-
curate estimates of influenza disease burden and result 
in a better selection of strategies for influenza prevention 
and control [25].
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